Safety
Toxic effects from subsequent treatment (including skin rash, diarrhoea, thrombocytopenia)
Adverse events associated with biopsies
Rate of re-biopsy
Summary of PICO to be used for assessment of evidence (systematic review)
Table 3 provides a summary of the PICO used to: (1) define the question for public funding,
(2) select the evidence to assess the safety and effectiveness of EGFR gene mutation
testing, with erlotinib and
(3) provide the evidence-based inputs for any decision-analysis modelling to determine the cost-effectiveness of EGFR gene mutation testing with erlotinib.
Table 3: Summary of PICO to define the question for public funding that assessment will investigate
Dostları ilə paylaş: |